1
|
Harrington CR, Storey JMD, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. J Biol Chem 2015; 290:10862-75. [PMID: 25759392 PMCID: PMC4409250 DOI: 10.1074/jbc.m114.616029] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Indexed: 12/15/2022] Open
Abstract
Alzheimer disease (AD) is a degenerative tauopathy characterized by aggregation of Tau protein through the repeat domain to form intraneuronal paired helical filaments (PHFs). We report two cell models in which we control the inherent toxicity of the core Tau fragment. These models demonstrate the properties of prion-like recruitment of full-length Tau into an aggregation pathway in which template-directed, endogenous truncation propagates aggregation through the core Tau binding domain. We use these in combination with dissolution of native PHFs to quantify the activity of Tau aggregation inhibitors (TAIs). We report the synthesis of novel stable crystalline leucomethylthioninium salts (LMTX®), which overcome the pharmacokinetic limitations of methylthioninium chloride. LMTX®, as either a dihydromesylate or a dihydrobromide salt, retains TAI activity in vitro and disrupts PHFs isolated from AD brain tissues at 0.16 μM. The Ki value for intracellular TAI activity, which we have been able to determine for the first time, is 0.12 μM. These values are close to the steady state trough brain concentration of methylthioninium ion (0.18 μM) that is required to arrest progression of AD on clinical and imaging end points and the minimum brain concentration (0.13 μM) required to reverse behavioral deficits and pathology in Tau transgenic mice.
Collapse
Affiliation(s)
- Charles R Harrington
- From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom, TauRx Therapeutics Ltd., Singapore 068805, and the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - John M D Storey
- TauRx Therapeutics Ltd., Singapore 068805, and the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Scott Clunas
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Kathleen A Harrington
- From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom
| | - David Horsley
- From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom
| | - Ahtsham Ishaq
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Steven J Kemp
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Christopher P Larch
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Colin Marshall
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Sarah L Nicoll
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Janet E Rickard
- From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom
| | - Michael Simpson
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - James P Sinclair
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Lynda J Storey
- the Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, United Kingdom
| | - Claude M Wischik
- From the School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZP, United Kingdom, TauRx Therapeutics Ltd., Singapore 068805, and
| |
Collapse
|
2
|
Rosseels J, Van den Brande J, Violet M, Jacobs D, Grognet P, Lopez J, Huvent I, Caldara M, Swinnen E, Papegaey A, Caillierez R, Buée-Scherrer V, Engelborghs S, Lippens G, Colin M, Buée L, Galas MC, Vanmechelen E, Winderickx J. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. J Biol Chem 2014; 290:4059-74. [PMID: 25540200 DOI: 10.1074/jbc.m114.627919] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A link between Tau phosphorylation and aggregation has been shown in different models for Alzheimer disease, including yeast. We used human Tau purified from yeast models to generate new monoclonal antibodies, of which three were further characterized. The first antibody, ADx201, binds the Tau proline-rich region independently of the phosphorylation status, whereas the second, ADx215, detects an epitope formed by the Tau N terminus when Tau is not phosphorylated at Tyr(18). For the third antibody, ADx210, the binding site could not be determined because its epitope is probably conformational. All three antibodies stained tangle-like structures in different brain sections of THY-Tau22 transgenic mice and Alzheimer patients, and ADx201 and ADx210 also detected neuritic plaques in the cortex of the patient brains. In hippocampal homogenates from THY-Tau22 mice and cortex homogenates obtained from Alzheimer patients, ADx215 consistently stained specific low order Tau oligomers in diseased brain, which in size correspond to Tau dimers. ADx201 and ADx210 additionally reacted to higher order Tau oligomers and presumed prefibrillar structures in the patient samples. Our data further suggest that formation of the low order Tau oligomers marks an early disease stage that is initiated by Tau phosphorylation at N-terminal sites. Formation of higher order oligomers appears to require additional phosphorylation in the C terminus of Tau. When used to assess Tau levels in human cerebrospinal fluid, the antibodies permitted us to discriminate patients with Alzheimer disease or other dementia like vascular dementia, indicative that these antibodies hold promising diagnostic potential.
Collapse
Affiliation(s)
- Joëlle Rosseels
- From Functional Biology, KU Leuven, Kasteelpark Arenberg 31 Box 2433, 3001 Heverlee, Belgium
| | - Jeff Van den Brande
- From Functional Biology, KU Leuven, Kasteelpark Arenberg 31 Box 2433, 3001 Heverlee, Belgium, ADx NeuroSciences NV, Technologiepark Zwijnaarde 4, 9052 Ghent, Belgium, Fujirebio Europe, Technologiepark Zwijnaarde 6, 9052 Ghent, Belgium
| | - Marie Violet
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Dirk Jacobs
- ADx NeuroSciences NV, Technologiepark Zwijnaarde 4, 9052 Ghent, Belgium
| | - Pierre Grognet
- Fujirebio Europe, Technologiepark Zwijnaarde 6, 9052 Ghent, Belgium
| | - Juan Lopez
- Université Lille Nord de France, 59000 Lille, France, CNRS, UMR8576 Structural and Functional Glycobiology, 59650 Villeneuve d'Ascq, France
| | - Isabelle Huvent
- Université Lille Nord de France, 59000 Lille, France, CNRS, UMR8576 Structural and Functional Glycobiology, 59650 Villeneuve d'Ascq, France
| | - Marina Caldara
- From Functional Biology, KU Leuven, Kasteelpark Arenberg 31 Box 2433, 3001 Heverlee, Belgium
| | - Erwin Swinnen
- From Functional Biology, KU Leuven, Kasteelpark Arenberg 31 Box 2433, 3001 Heverlee, Belgium
| | - Anthony Papegaey
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Raphaëlle Caillierez
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Valerie Buée-Scherrer
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Sebastiaan Engelborghs
- the Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, 2610 Wilrijk, Belgium, and the Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, 2660 Antwerp, Belgium
| | - Guy Lippens
- Université Lille Nord de France, 59000 Lille, France, CNRS, UMR8576 Structural and Functional Glycobiology, 59650 Villeneuve d'Ascq, France
| | - Morvane Colin
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Luc Buée
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Marie-Christine Galas
- INSERM, UMR1172, JPArc, Alzheimer & Tauopathies, Rue Polonovski, 59045 Lille, France, the Faculté de Médecine, Université de Lille, Place de Verdun, 59045 Lille, France, the Memory Clinic, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France
| | - Eugeen Vanmechelen
- ADx NeuroSciences NV, Technologiepark Zwijnaarde 4, 9052 Ghent, Belgium,
| | - Joris Winderickx
- From Functional Biology, KU Leuven, Kasteelpark Arenberg 31 Box 2433, 3001 Heverlee, Belgium,
| |
Collapse
|
3
|
Deng SS, Wu LY, Wang YC, Cao PR, Xu L, Li QR, Liu M, Zhang L, Jiang YJ, Yang XY, Sun SN, Tan MJ, Qian M, Zang Y, Feng L, Li J. Protein kinase A rescues microtubule affinity-regulating kinase 2-induced microtubule instability and neurite disruption by phosphorylating serine 409. J Biol Chem 2014; 290:3149-60. [PMID: 25512381 DOI: 10.1074/jbc.m114.629873] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Microtubule affinity-regulating kinase 2 (MARK2)/PAR-1b and protein kinase A (PKA) are both involved in the regulation of microtubule stability and neurite outgrowth, but whether a direct cross-talk exists between them remains unclear. Here, we found the disruption of microtubule and neurite outgrowth induced by MARK2 overexpression was blocked by active PKA. The interaction between PKA and MARK2 was confirmed by coimmunoprecipitation and immunocytochemistry both in vitro and in vivo. PKA was found to inhibit MARK2 kinase activity by phosphorylating a novel site, serine 409. PKA could not reverse the microtubule disruption effect induced by a serine 409 to alanine (Ala) mutant of MARK2 (MARK2 S409A). In contrast, mutation of MARK2 serine 409 to glutamic acid (Glu) (MARK2 S409E) did not affect microtubule stability and neurite outgrowth. We propose that PKA functions as an upstream inhibitor of MARK2 in regulating microtubule stability and neurite outgrowth by directly interacting and phosphorylating MARK2.
Collapse
Affiliation(s)
- Si-Si Deng
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Le-Yu Wu
- Department of Neuropharmacology, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Ya-Chao Wang
- School of Life Sciences, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China
| | - Peng-Rong Cao
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Lei Xu
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Qian-Ru Li
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Meng Liu
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Lun Zhang
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Yue-Jing Jiang
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China
| | - Xiao-Yu Yang
- Department of Neuropharmacology, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Sheng-Nan Sun
- The Chemical Proteomics Center and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China, and
| | - Min-jia Tan
- The Chemical Proteomics Center and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China, and
| | - Min Qian
- School of Life Sciences, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China
| | - Yi Zang
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China,
| | - Linyin Feng
- Department of Neuropharmacology, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China,
| | - Jia Li
- From the National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shoujing Road, Shanghai 201203, China, School of Life Sciences, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China
| |
Collapse
|
4
|
Xu W, Ge Y, Liu Z, Gong R. Glycogen synthase kinase 3β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion. J Biol Chem 2014; 290:1348-63. [PMID: 25468908 DOI: 10.1074/jbc.m114.593830] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Reminiscent of neural repair, following podocyte depletion, remnant-surviving podocytes exhibit a considerable adaptive capacity to expand and cover the denuded renal glomerular basement membrane. Microtubules, one of the principal cytoskeletal components of podocyte major processes, play a crucial role in podocyte morphogenesis and podocyte process outgrowth, branching, and elongation. Here, we demonstrated that the microtubule-associated proteins Tau and collapsin response mediator protein (CRMP) 2, key regulators of microtubule dynamics, were abundantly expressed by glomerular podocytes in vivo and in vitro, interacted with glycogen synthase kinase (GSK)3β, and served as its putative substrates. GSK3β overactivity induced by adriamycin injury or by a constitutively active mutant of GSK3β augmented phosphorylation of Tau and CRMP2, concomitant with microtubule depolymerization, cell body shrinkage, and shortening of podocyte processes. Conversely, inhibition of GSK3β by a dominant negative mutant or by lithium, a Food and Drug Administration-approved neuroprotective mood stabilizer, diminished Tau and CRMP2 phosphorylation, resulting in microtubule polymerization, podocyte expansion, and lengthening of podocyte processes. In a mouse model of adriamycin-induced podocyte depletion and nephropathy, delayed administration of a single low dose of lithium attenuated proteinuria and ameliorated progressive glomerulosclerosis despite no correction of podocytopenia. Mechanistically, lithium therapy obliterated GSK3β overactivity, mitigated phosphorylation of Tau and CRMP2, and enhanced microtubule polymerization and stabilization in glomeruli in adriamycin-injured kidneys, associated with elongation of podocyte major processes. Collectively, our findings suggest that the GSK3β-dictated podocyte microtubule dynamics might serve as a novel therapeutic target to reinforce the compensatory glomerular adaptation to podocyte loss.
Collapse
Affiliation(s)
- Weiwei Xu
- From the National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China and the Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903
| | - Yan Ge
- the Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903
| | - Zhihong Liu
- From the National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China and
| | - Rujun Gong
- the Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903
| |
Collapse
|
5
|
Diner I, Hales CM, Bishof I, Rabenold L, Duong DM, Yi H, Laur O, Gearing M, Troncoso J, Thambisetty M, Lah JJ, Levey AI, Seyfried NT. Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease. J Biol Chem 2014; 289:35296-313. [PMID: 25355317 DOI: 10.1074/jbc.m114.562959] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Recent evidence indicates that U1-70K and other U1 small nuclear ribonucleoproteins are Sarkosyl-insoluble and associate with Tau neurofibrillary tangles selectively in Alzheimer disease (AD). Currently, the mechanisms underlying the conversion of soluble nuclear U1 small nuclear ribonucleoproteins into insoluble cytoplasmic aggregates remain elusive. Based on the biochemical and subcellular distribution properties of U1-70K in AD, we hypothesized that aggregated U1-70K itself or other biopolymers (e.g. proteins or nucleic acids) interact with and sequester natively folded soluble U1-70K into insoluble aggregates. Here, we demonstrate that total homogenates from AD brain induce soluble U1-70K from control brain or recombinant U1-70K to become Sarkosyl-insoluble. This effect was not dependent on RNA and did not correlate with detergent-insoluble Tau levels as AD homogenates with reduced levels of these components were still capable of inducing U1-70K aggregation. In contrast, proteinase K-treated AD homogenates and Sarkosyl-soluble AD fractions were unable to induce U1-70K aggregation, indicating that aggregated proteins in AD brain are responsible for inducing soluble U1-70K aggregation. It was determined that the C terminus of U1-70K, which harbors two disordered low complexity (LC) domains, is necessary for U1-70K aggregation. Moreover, both LC1 and LC2 domains were sufficient for aggregation. Finally, protein cross-linking and mass spectrometry studies demonstrated that a U1-70K fragment harboring the LC1 domain directly interacts with aggregated U1-70K in AD brain. Our results support a hypothesis that aberrant forms of U1-70K in AD can directly sequester soluble forms of U1-70K into insoluble aggregates.
Collapse
Affiliation(s)
- Ian Diner
- From the Departments of Biochemistry and the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322
| | - Chadwick M Hales
- the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 Neurology
| | - Isaac Bishof
- From the Departments of Biochemistry and the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322
| | - Lake Rabenold
- From the Departments of Biochemistry and the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322
| | - Duc M Duong
- From the Departments of Biochemistry and the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322
| | - Hong Yi
- Emory University School of Medicine, Atlanta, Georgia 30322 Robert P. Apkarian Integrated Electron Microscopy Core
| | - Oskar Laur
- Emory University School of Medicine, Atlanta, Georgia 30322 Division of Microbiology, and Yerkes Research Center, Emory University, Atlanta, Georgia 30322
| | - Marla Gearing
- the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 the Departments of Experimental Pathology and
| | - Juan Troncoso
- Pathology and Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205
| | | | - James J Lah
- the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 Neurology
| | - Allan I Levey
- the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 Neurology
| | - Nicholas T Seyfried
- From the Departments of Biochemistry and the Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 Neurology,
| |
Collapse
|
6
|
Tepper K, Biernat J, Kumar S, Wegmann S, Timm T, Hübschmann S, Redecke L, Mandelkow EM, Müller DJ, Mandelkow E. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem 2014; 289:34389-407. [PMID: 25339173 PMCID: PMC4256367 DOI: 10.1074/jbc.m114.611368] [Citation(s) in RCA: 108] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Abnormal phosphorylation (“hyperphosphorylation”) and aggregation of Tau protein are hallmarks of Alzheimer disease and other tauopathies, but their causative connection is still a matter of debate. Tau with Alzheimer-like phosphorylation is also present in hibernating animals, mitosis, or during embryonic development, without leading to pathophysiology or neurodegeneration. Thus, the role of phosphorylation and the distinction between physiological and pathological phosphorylation needs to be further refined. So far, the systematic investigation of highly phosphorylated Tau was difficult because a reliable method of preparing reproducible quantities was not available. Here, we generated full-length Tau (2N4R) in Sf9 cells in a well defined phosphorylation state containing up to ∼20 phosphates as judged by mass spectrometry and Western blotting with phospho-specific antibodies. Despite the high concentration in living Sf9 cells (estimated ∼230 μm) and high phosphorylation, the protein was not aggregated. However, after purification, the highly phosphorylated protein readily formed oligomers, whereas fibrils were observed only rarely. Exposure of mature primary neuronal cultures to oligomeric phospho-Tau caused reduction of spine density on dendrites but did not change the overall cell viability.
Collapse
Affiliation(s)
- Katharina Tepper
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany
| | - Jacek Biernat
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany
| | - Satish Kumar
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany
| | - Susanne Wegmann
- the Department of Biosystems Science and Engineering, ETHZ, 4058 Basel, Switzerland
| | - Thomas Timm
- the Institute of Biochemistry, Faculty of Medicine, Justus-Liebig-University, 35390 Giessen, Germany, and
| | - Sabrina Hübschmann
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany
| | - Lars Redecke
- the Joint Laboratory for Structural Biology of Infection and Inflammation, University of Hamburg and University of Lübeck, ℅DESY, 22603 Hamburg, Germany
| | - Eva-Maria Mandelkow
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany
| | - Daniel J Müller
- the Department of Biosystems Science and Engineering, ETHZ, 4058 Basel, Switzerland
| | - Eckhard Mandelkow
- From the DZNE, German Center for Neurodegenerative Diseases, 53175 Bonn, Germany, the CAESAR Research Center, 53175 Bonn, Germany,
| |
Collapse
|
7
|
Abstract
Regional glucose hypometabolism is a defining feature of Alzheimer disease (AD). One emerging link between glucose hypometabolism and progression of AD is the nutrient-responsive post-translational O-GlcNAcylation of nucleocytoplasmic proteins. O-GlcNAc is abundant in neurons and occurs on both tau and amyloid precursor protein. Increased brain O-GlcNAcylation protects against tau and amyloid-β peptide toxicity. Decreased O-GlcNAcylation occurs in AD, suggesting that glucose hypometabolism may impair the protective roles of O-GlcNAc within neurons and enable neurodegeneration. Here, we review how O-GlcNAc may link cerebral glucose hypometabolism to progression of AD and summarize data regarding the protective role of O-GlcNAc in AD models.
Collapse
Affiliation(s)
- Yanping Zhu
- From the Departments of Molecular Biology and Biochemistry and Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | - Xiaoyang Shan
- From the Departments of Molecular Biology and Biochemistry and
| | - Scott A Yuzwa
- From the Departments of Molecular Biology and Biochemistry and
| | - David J Vocadlo
- From the Departments of Molecular Biology and Biochemistry and Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| |
Collapse
|
8
|
Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M. The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation. J Biol Chem 2014; 289:33927-44. [PMID: 25331948 DOI: 10.1074/jbc.m114.608091] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
We have previously shown that the L-type calcium channel (LCC) antagonist nilvadipine reduces brain amyloid-β (Aβ) accumulation by affecting both Aβ production and Aβ clearance across the blood-brain barrier (BBB). Nilvadipine consists of a mixture of two enantiomers, (+)-nilvadipine and (-)-nilvadipine, in equal proportion. (+)-Nilvadipine is the active enantiomer responsible for the inhibition of LCC, whereas (-)-nilvadipine is considered inactive. Both nilvadipine enantiomers inhibit Aβ production and improve the clearance of Aβ across the BBB showing that these effects are not related to LCC inhibition. In addition, treatment of P301S mutant human Tau transgenic mice (transgenic Tau P301S) with (-)-nilvadipine reduces Tau hyperphosphorylation at several Alzheimer disease (AD) pertinent epitopes. A search for the mechanism of action of (-)-nilvadipine revealed that this compound inhibits the spleen tyrosine kinase (Syk). We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes. We show that Syk inhibition induces an increased phosphorylation of the inhibitory Ser-9 residue of glycogen synthase kinase-3β, a primary Tau kinase involved in Tau phosphorylation, by activating protein kinase A, providing a mechanism explaining the reduction of Tau phosphorylation at GSK3β-dependent epitopes following Syk inhibition. Altogether our data highlight Syk as a promising target for preventing both Aβ accumulation and Tau hyperphosphorylation in AD.
Collapse
Affiliation(s)
- Daniel Paris
- From the Roskamp Institute, Sarasota, Florida 34243
| | | | | | - Gary Laco
- From the Roskamp Institute, Sarasota, Florida 34243
| | | | - Yong Lin
- From the Roskamp Institute, Sarasota, Florida 34243
| | - Chao Jin
- From the Roskamp Institute, Sarasota, Florida 34243
| | | | | |
Collapse
|
9
|
Arif M, Wei J, Zhang Q, Liu F, Basurto-Islas G, Grundke-Iqbal I, Iqbal K. Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. J Biol Chem 2014; 289:27677-91. [PMID: 25128526 PMCID: PMC4183805 DOI: 10.1074/jbc.m114.565358] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 08/11/2014] [Indexed: 12/22/2022] Open
Abstract
Abnormal hyperphosphorylation of Tau leads to the formation of neurofibrillary tangles, a hallmark of Alzheimer disease (AD), and related tauopathies. The phosphorylation of Tau is regulated by protein phosphatase 2A (PP2A), which in turn is modulated by endogenous inhibitor 2 (I2 (PP2A)). In AD brain, I2 (PP2A) is translocated from neuronal nucleus to cytoplasm, where it inhibits PP2A activity and promotes abnormal phosphorylation of Tau. Here we describe the identification of a potential nuclear localization signal (NLS) in the C-terminal region of I2 (PP2A) containing a conserved basic motif, (179)RKR(181), which is sufficient for directing its nuclear localization. The current study further presents an inducible cell model (Tet-Off system) of AD-type abnormal hyperphosphorylation of Tau by expressing I2 (PP2A) in which the NLS was inactivated by (179)RKR(181) → AAA along with (168)KR(169) → AA mutations. In this model, the mutant NLS (mNLS)-I2 (PP2A) (I2 (PP2A)AA-AAA) was retained in the cell cytoplasm, where it physically interacted with PP2A and inhibited its activity. Inhibition of PP2A was associated with the abnormal hyperphosphorylation of Tau, which resulted in microtubule network instability and neurite outgrowth impairment. Expression of mNLS-I2 (PP2A) activated CAMKII and GSK-3β, which are Tau kinases regulated by PP2A. The immunoprecipitation experiments showed the direct interaction of I2 (PP2A) with PP2A and GSK-3β but not with CAMKII. Thus, the cell model provides insights into the nature of the potential NLS and the mechanistic relationship between I2 (PP2A)-induced inhibition of PP2A and hyperphosphorylation of Tau that can be utilized to develop drugs preventing Tau pathology.
Collapse
Affiliation(s)
- Mohammad Arif
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Jianshe Wei
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Qi Zhang
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Fei Liu
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Gustavo Basurto-Islas
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Inge Grundke-Iqbal
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| | - Khalid Iqbal
- From the Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314
| |
Collapse
|
10
|
Grüning CSR, Mirecka EA, Klein AN, Mandelkow E, Willbold D, Marino SF, Stoldt M, Hoyer W. Alternative conformations of the Tau repeat domain in complex with an engineered binding protein. J Biol Chem 2014; 289:23209-23218. [PMID: 24966331 DOI: 10.1074/jbc.m114.560920] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The aggregation of Tau into paired helical filaments is involved in the pathogenesis of several neurodegenerative diseases, including Alzheimer disease. The aggregation reaction is characterized by conformational conversion of the repeat domain, which partially adopts a cross-β-structure in the resulting amyloid-like fibrils. Here, we report the selection and characterization of an engineered binding protein, β-wrapin TP4, targeting the Tau repeat domain. TP4 was obtained by phage display using the four-repeat Tau construct K18ΔK280 as a target. TP4 binds K18ΔK280 as well as the longest isoform of human Tau, hTau40, with nanomolar affinity. NMR spectroscopy identified two alternative TP4-binding sites in the four-repeat domain, with each including two hexapeptide motifs with high β-sheet propensity. Both binding sites contain the aggregation-determining PHF6 hexapeptide within repeat 3. In addition, one binding site includes the PHF6* hexapeptide within repeat 2, whereas the other includes the corresponding hexapeptide Tau(337-342) within repeat 4, denoted PHF6**. Comparison of TP4-binding with Tau aggregation reveals that the same regions of Tau are involved in both processes. TP4 inhibits Tau aggregation at substoichiometric concentration, demonstrating that it interferes with aggregation nucleation. This study provides residue-level insight into the interaction of Tau with an aggregation inhibitor and highlights the structural flexibility of Tau.
Collapse
Affiliation(s)
- Clara S R Grüning
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany
| | - Ewa A Mirecka
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany
| | - Antonia N Klein
- Institute of Structural Biochemistry (ICS-6), Research Centre Jülich, 52425 Jülich, Germany
| | - Eckhard Mandelkow
- German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, and; Center of Advanced European Studies And Research (CAESAR), 53175 Bonn, Germany
| | - Dieter Willbold
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany,; Institute of Structural Biochemistry (ICS-6), Research Centre Jülich, 52425 Jülich, Germany
| | - Stephen F Marino
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany
| | - Matthias Stoldt
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany,; Institute of Structural Biochemistry (ICS-6), Research Centre Jülich, 52425 Jülich, Germany
| | - Wolfgang Hoyer
- Institute of Physical Biology, Heinrich-Heine-Universität, 40204 Düsseldorf, Germany,; Institute of Structural Biochemistry (ICS-6), Research Centre Jülich, 52425 Jülich, Germany,.
| |
Collapse
|
11
|
Abstract
Work over the past 4 years indicates that multiple proteins associated with neurodegenerative diseases, especially Tau and α-synuclein, can propagate aggregates between cells in a prion-like manner. This means that once an aggregate is formed it can escape the cell of origin, contact a connected cell, enter the cell, and induce further aggregation via templated conformational change. The prion model predicts a key role for extracellular protein aggregates in mediating progression of disease. This suggests new therapeutic approaches based on blocking neuronal uptake of protein aggregates and promoting their clearance. This will likely include therapeutic antibodies or small molecules, both of which can be developed and optimized in vitro prior to preclinical studies.
Collapse
Affiliation(s)
- Brandon B Holmes
- From the Department of Neurology, Washington University in St. Louis, St. Louis, Missouri 63110
| | - Marc I Diamond
- From the Department of Neurology, Washington University in St. Louis, St. Louis, Missouri 63110
| |
Collapse
|
12
|
Abstract
Brain metabolism is thought to be maintained by neuronal-glial metabolic coupling. Glia take up glutamate from the synaptic cleft for conversion into glutamine, triggering glial glycolysis and lactate production. This lactate is shuttled into neurons and further metabolized. The origin and role of lactate in severe traumatic brain injury (TBI) remains controversial. Using a modified weight drop model of severe TBI and magnetic resonance (MR) spectroscopy with infusion of (13)C-labeled glucose, lactate, and acetate, the present study investigated the possibility that neuronal-glial metabolism is uncoupled following severe TBI. Histopathology of the model showed severe brain injury with subarachnoid and hemorrhage together with glial cell activation and positive staining for Tau at 90 min post-trauma. High resolution MR spectroscopy of brain metabolites revealed significant labeling of lactate at C-3 and C-2 irrespective of the infused substrates. Increased (13)C-labeled lactate in all study groups in the absence of ischemia implied activated astrocytic glycolysis and production of lactate with failure of neuronal uptake (i.e. a loss of glial sensing for glutamate). The early increase in extracellular lactate in severe TBI with the injured neurons rendered unable to pick it up probably contributes to a rapid progression toward irreversible injury and pan-necrosis. Hence, a method to detect and scavenge the excess extracellular lactate on site or early following severe TBI may be a potential primary therapeutic measure.
Collapse
Affiliation(s)
- Sanju Lama
- From the Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada and
| | - Roland N Auer
- the Hôpital Ste-Justine, Département de Pathologie, Université de Montréal, Montreal, Québec H3T 1C5, Canada
| | - Randy Tyson
- From the Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada and
| | - Clare N Gallagher
- From the Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada and
| | - Boguslaw Tomanek
- From the Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada and
| | - Garnette R Sutherland
- From the Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada and
| |
Collapse
|
13
|
Kumar S, Tepper K, Kaniyappan S, Biernat J, Wegmann S, Mandelkow EM, Müller DJ, Mandelkow E. Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity. J Biol Chem 2014; 289:20318-32. [PMID: 24825901 PMCID: PMC4106345 DOI: 10.1074/jbc.m114.554725] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Several neurodegenerative diseases are characterized by the aggregation and posttranslational modifications of Tau protein. Its “repeat domain” (TauRD) is mainly responsible for the aggregation properties, and oligomeric forms are thought to dominate the toxic effects of Tau. Here we investigated the conformational transitions of this domain during oligomerization and aggregation in different states of β-propensity and pseudo-phosphorylation, using several complementary imaging and spectroscopic methods. Although the repeat domain generally aggregates more readily than full-length Tau, its aggregation was greatly slowed down by phosphorylation or pseudo-phosphorylation at the KXGS motifs, concomitant with an extended phase of oligomerization. Analogous effects were observed with pro-aggregant variants of TauRD. Oligomers became most evident in the case of the pro-aggregant mutant TauRDΔK280, as monitored by atomic force microscopy, and the fluorescence lifetime of Alexa-labeled Tau (time-correlated single photon counting (TCSPC)), consistent with its pronounced toxicity in mouse models. In cell models or primary neurons, neither oligomers nor fibrils of TauRD or TauRDΔK280 had a toxic effect, as seen by assays with lactate dehydrogenase and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, respectively. However, oligomers of pro-aggregant TauRDΔK280 specifically caused a loss of spine density in differentiated neurons, indicating a locally restricted impairment of function.
Collapse
Affiliation(s)
- Satish Kumar
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and
| | - Katharina Tepper
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany
| | - Senthilvelrajan Kaniyappan
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and
| | - Jacek Biernat
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and the Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany
| | - Susanne Wegmann
- the Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zürich, Basel, 4058 Basel, Switzerland
| | - Eva-Maria Mandelkow
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and the Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany
| | - Daniel J Müller
- the Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zürich, Basel, 4058 Basel, Switzerland
| | - Eckhard Mandelkow
- From the German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany, the Max Planck Institute for Neurological Research, Hamburg Outstation, c/o DESY, 22607 Hamburg, Germany, and the Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany,
| |
Collapse
|